Don’t Crash & Burn: Why Cutting Your Quality Department’s Budget is not a Good Idea

By Jennifer Dawson, MHA, LSSBB, CPHQ, DLM(ASCP)QIHC, QLC, SLS  bio Do you think that you can improve your organization's bottom line by reducing the budget to your quality program and … [Read more...]


Fanning the Flames

By Dan Scungio, MT (ASCP), SLS, CQA (ASQ)  bio Story #1: The fire started in the university chemistry laboratory when a research student used a flammable chemical too close to the open … [Read more...]


Industry Trends: New Report Sheds Light on DX Tech Capital Flows

The health care industry has raised $5 billion in venture fund investment in the first half of 2017 and is well on pace to smash the single year record of $7.5 billion set in 2015, according to … [Read more...]


FDA Watch: Diagnostics Industry Is Losing a Longstanding “Frenemy”

The diagnostics community is saying goodbye to a frenemy of 25 years. On Aug. 29, Alberto Gutierrez, director of the FDA Office of In Vitro Diagnostics (OIVD), announced that he will step down from … [Read more...]


Draft 2018 CLFS Reveals Fundamental Flaws in PAMA Reporting Exercise; Time to Take Action

By Lâle White  bio As XIFIN predicted, the PAMA reporting exercise has resulted in significant proposed laboratory fee cuts. In fact, the multi-year decrease for the top 20 laboratory tests … [Read more...]


Company of the Month: Interpace Diagnostics

Question: What do Parsippany, NJ-based Interpace Diagnostics and butter have in common? Answer: They're both on a roll. July 27: The molecular lab announces that Cigna will cover its ThyGenX … [Read more...]


The Dx Pipeline: A Roundup of the Month’s Key New Product Launches

Although it did not launch any new products, Quest announced that its existing low density lipoprotein (LDL) cholesterol tests are using a new calculation that not only improves accuracy but also … [Read more...]


Medicare Reimbursement: 4 Molecular Assays Score Big Coverage Wins

Molecular labs continue to gain ground with Medicare securing four key approvals via finalization of Local Coverage Determinations (LCDs) issued by principal contractor Palmetto GBA this spring. All … [Read more...]


Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Strategic alliance rather than M&A remains the preferred form of strategic interaction in the lab industry. M&A The preference of diagnostic companies to work with rather than digest each … [Read more...]


Dx Earnings Report: Strong Q2 Enables Lab Companies to Consolidate Q1 Gains

The lab industry consolidated its early 2017 gains with an almost equally strong Q2. Although there were some notable declines, most companies posted gains at or above Wall Street expectations. Here's … [Read more...]